Oncology - Breast Cancer | |
|---|---|
| Study Name | Principal Investigator |
| NRG-BR007 – A De-Escalation of Breast Radiation Trial for Hormone Sensitive, Her2 Negative, Oncotype Recurrence Score less than or equal 18 Breast cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Raimonda Goldman, MD |
| EA1181 (CompassHER2-pCR) – A de-escalation study assessing the effect of decreasing chemotherapy in patients with HER2 positive breast cancer, with no evidence of cancer remaining after pre-operative chemotherapy and HER2-targeted therapy. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| A191901 GETSET Study – An Additional Support Program Via Text Messaging and Telephone-Based Counselling for Breast Cancer Patients Receiving Hormonal Therapy. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| S1501 – Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
| A011801 – A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib”. For more information about this study and to inquire about eligibility, please contact the Oncology Research Program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
Oncology - Colorectal Cancer | |
| Study Name | Principal Investigator |
| A221805 – A Study of Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in patients with Stage II-III Colorectal Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
| A021806 – A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology Research Program at 201-530-7934. Read more. |
Steve Kwon, MD |
| The JANUS RECTAL Cancer Trial – A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
Oncology - Lung Cancer | |
| Study Name | Principal Investigator |
| MRTX849 – A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation. For more information about this study and to inquire about eligibility, please contact the Oncology Research Program at 201-530-7934. Read more. |
Yadyra Rivera, MD |
Oncology - Pancreatic Cancer | |
| Study Name | Principal Investigator |
| EA2186 – A Study Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan For Older Patients With Pancreatic Cancer That Has Spread. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
Oncology - Prostate Cancer | |
| Study Name | Principal Investigator |
| S1802 – A Study of Standard Systemic Therapy with or Without Definitive Treatment in Treating Patients with Metastatic Prostate Cancer. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Jason Lee, MD |
Oncology - Skin Cancer | |
| Study Name | Principal Investigator |
| Alpha Tau CTP-SCC-03 – A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma. For more information about this study and to inquire about eligibility, please contact the Oncology research program at 201-530-7934. Read more. |
Benjamin Rosenbluth, MD |
